Ex Vivo Generation of Human Alloantigen-Specific Regulatory T Cells from CD4posCD25high T Cells for Immunotherapy by Peters, Jorieke H. et al.
Ex Vivo Generation of Human Alloantigen-Specific
Regulatory T Cells from CD4
posCD25
high T Cells for
Immunotherapy
Jorieke H. Peters
1, Luuk B. Hilbrands
2, Hans J. P. M. Koenen
1, Irma Joosten
1*
1Department of Bloodtransfusion and Transplantation Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2Department of
Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Abstract
Background: Regulatory T cell (Treg) based immunotherapy is a potential treatment for several immune disorders. By now,
this approach proved successful in preclinical animal transplantation and auto-immunity models. In these models the
success of Treg based immunotherapy crucially depends on the antigen-specificity of the infused Treg population. For the
human setting, information is lacking on how to generate Treg with direct antigen-specificity ex vivo to be used for
immunotherapy.
Methodology/Principal Findings: Here, we demonstrate that in as little as two stimulation cycles with HLA mismatched
allogeneic stimulator cells and T cell growth factors a very high degree of alloantigen-specificity was reached in magnetic
bead isolated human CD4
posCD25
high Treg. Efficient increases in cell numbers were obtained. Primary allogeneic stimulation
appeared a prerequisite in the generation of alloantigen-specific Treg, while secondary allogeneic or polyclonal stimulation
with anti-CD3 plus anti-CD28 monoclonal antibodies enriched alloantigen-specificity and cell yield to a similar extent.
Conclusions/Significance: The ex vivo expansion protocol that we describe will very likely increase the success of clinical
Treg-based immunotherapy, and will help to induce tolerance to selected antigens, while minimizing general immune
suppression. This approach is of particular interest for recipients of HLA mismatched transplants.
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Introduction
Regulatory T cells (Treg) play a critical role in various
immunological processes. These cells dampen immune responses,
which is important in maintenance of (self-) tolerance and
homeostasis. Immunotherapy based on Treg (either in vivo
facilitation of Treg or infusion of ex vivo isolated / manipulated
Treg) is therefore a potential treatment for many immune
disorders. Such an approach has been proven successful in animal
models of stem cell transplantation [1–7], solid organ transplan-
tation [8,9], auto-immunity [10–14] and even in infertility [15].
Treg therapy in human patients will require high cell numbers,
which might be obtained by ex vivo expansion. It has been shown
that human naturally occurring CD4
posCD25
high Treg can be
expanded polyclonally, by using anti-CD3 and anti-CD28
antibody stimulation in combination with IL-2 and/or IL-15
[16–21]. These polyclonal expansion protocols greatly increase
Treg numbers, while preserving suppressive capacity. However,
there are some drawbacks regarding clinical application of
polyclonally expanded Treg. First, since this type of activation
encompasses Treg with a broad range of specificities, the infused
polyclonal Treg may suppress immune responses other than the
target response, thereby increasing the risk for opportunistic
infections and tumor-growth. Second, due to the low percentage of
Treg within a polyclonal cell pool that is specific for a given target
antigen, large numbers of Treg need to be infused. These
difficulties could be overcome by using antigen-specific Treg. In
animal models, antigen-specific Treg have been shown to be far
more efficient than polyclonal Treg [4,6,7,12–14]. Even as few as
5610
3 antigen-specific Treg were sufficient to prevent the onset of
diabetes in a NOD model [14].
For the human setting, information is scarce on how to generate
sufficient numbers of antigen-specific Treg ex-vivo from naturally
occurring Treg [22]. The aim of this study was to design a
successful strategy to obtain high numbers of Treg with direct
alloantigen-specificity for use in transplantation settings. Based on
previous findings, we hypothesized that it would be beneficial to
combine polyclonal stimulation, to boost expansion, with alloan-
tigen stimulation, to increase antigen-specificity. To test this
hypothesis, we alternated these two stimulation methods in
primary and secondary Treg expansion cycles and assessed cell
numbers, phenotype, function and antigen-specificity before and
after expansion. Thus, we succeeded in defining a protocol that
yields high numbers of strictly alloantigen-specific human Treg.
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Optimal conditions for primary and secondary expansion
cycles
With the objective to obtain the highest numbers of functionally
active Treg with optimal direct alloantigen-specificity, we devised
four expansion strategies, employing polyclonal and alloantigen-
specific stimulation in two subsequent cycles of Treg expansion
(Figure 1). The cells that were obtained with these expansion
strategies were compared in terms of absolute cell numbers,
phenotype, suppressive capacity, antigen-specificity and anergy.
Prior to analysis of the four selected Treg expansion strategies,
individual expansion cycles were optimized, with regard to
strength and mode of stimulation.
Cell sorting based on multiple surface markers such as CD25,
CD127, CD62L and CD27 yields a high purity of FoxP3
pos Treg.
However, these tools are not available for clinical grade purposes.
Therefore, we specifically chose to use magnetic bead isolation
for purification of Treg, as this most closely fits with the
currently available GMP isolation tools. Cells isolated by this
procedure expressed CD25 and FoxP3, but not CD127
(Figure 2A), thus displaying a typical Treg phenotype [23–26].
In contrast, CD4
posCD25
neg conventional T cells (Tconv) did not
express FoxP3 or CD25, and were positive for CD127. The
majority of the isolated Treg as well as Tconv expressed the
differentiation marker CD27, not its ligand CD70, and were
positive for CD62L.
The freshly isolated Treg were hyporesponsive upon restimu-
lation (Figure 2B) and able to suppress proliferation of autologous
CD4
posCD25
neg T cells upon stimulation with alloantigen
(Figure 2C, D and E), .50% suppression was seen with
Tresp:Treg ratios of 4:1 or lower (Figure 2C). Tconv were not
anergic, nor suppressive.
For alloantigen driven expansion, the optimal strength of
alloantigen stimulation was determined by titrating irradiated
HLA mismatched allogeneic PBMC into Treg cultures, in the
presence of exogenous IL-2 and IL-15. In a primary MLR,
proliferation was maximal with stimulator:responder ratios of 4:1
(Figure 3A). Secondary stimulation with alloantigen showed
similar results (Figure 3B). The data shown in Figure 3B were
obtained with Treg primed with alloantigen, but similar results
were observed when polyclonally primed Treg were used (data not
shown). Consequently, for expansion experiments, a stimulator:-
responder ratio of 4:1 was used. Interestingly, a higher number of
HLA-DRB1 mismatches between stimulator and responder
resulted in higher expansion rates (P,0.05) (Figure 3C). Mis-
matches at other HLA genes did not significantly correlate with
expansion efficiency (data not shown).
For polyclonal stimulation we used CD3 and CD28 triggering,
and we compared anti-CD3+ anti-CD28 mAb coated microbeads
with platebound anti-CD3+ soluble anti-CD28 mAb stimulation.
For primary expansion of Treg, higher proliferation rates were
achieved with beads as compared to platebound anti-CD3+
soluble anti-CD28 mAb (Figure 4A). Cell yield after expansion of
Treg with either stimulation mode, using optimal dosage, was
higher for anti-CD3+ anti-CD28 bead stimulation as compared to
platebound anti-CD3+ soluble anti-CD28 stimulation (Figure 4B).
To explain these differences, we assessed cell division and survival
in Treg cultures for both stimuli (Figure 4C). Upon stimulation
with anti-CD3+ anti-CD28 mAb coated beads, the majority of cells
were triggered to proliferate as determined by CFSE dilution.
Expression of 7AAD, a marker for late apoptotic cells, was low. Bcl-
2, an anti-apoptotic protein, was expressed by 70–85% of the cells.
Further gating revealed that the dividing cell population specifically
expressed Bcl-2. Upon stimulation with platebound anti-CD3+
soluble anti-CD28 mAb, and independent of the concentration
used, a large portion of cells was not triggered to proliferate. Again
7AAD staining was low. The percentage of cells that expressed Bcl-2
was lower as compared to cells stimulated with anti-CD3+ anti-
CD28 beads, this correlated with the percentage of dividing cells.
The results indicate that the lower cell yield after stimulation of Treg
with platebound anti-CD3+ soluble anti-CD28 mAb is merely
caused by less efficient triggering of Treg proliferation, and is not the
result of enhanced cell death.
These experiments were also conducted for secondary poly-
clonal stimulation. In this situation, platebound anti-CD3+ soluble
anti-CD28 stimulation was superior as a secondary stimulus as
compared to anti-CD3+ anti-CD28 microbead stimulation
(Figure 5A). Expansion cultures stimulated with platebound anti-
CD3+ soluble anti-CD28 yielded more Treg as compared to
cultures stimulated with anti-CD3+ anti-CD28 beads (Figure 5B).
Attempting to explain these findings, we again assessed cell
division and survival in Treg cultures using both stimuli
(Figure 5C). In contrast to the results after primary stimulation,
both polyclonal stimuli now induced massive proliferation as
assessed by CFSE dilution. Also, both 7AAD staining and Bcl-2
expression were comparable between Treg cultures stimulated
with either anti-CD3+ anti-CD28 beads or platebound anti-CD3+
soluble anti-CD28 mAb. The data shown in Figure 5 were
obtained with Treg primed with anti-CD3+ anti-CD28 beads,
similar results were observed when alloantigen primed Treg were
used (data not shown). Overall, these data prompted us to use
Figure 1. Schematic overview of expansion strategies. Treg were expanded in two cycles, in which alloantigen and polyclonal stimulation was
alternated, resulting in four distinct strategies: two subsequent cycles with alloantigen stimulation; primary cycle with alloantigen stimulus and
secondary cycle with polyclonal stimulus; primary cycle with polyclonal stimulus and secondary cycle with alloantigen stimulus; and two subsequent
cycles with polyclonal stimulation.
doi:10.1371/journal.pone.0002233.g001
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restimulation in further experiments.
Several reports have described the use of high dose IL-2 in Treg
expansion protocols [16,17]. Our laboratory and others have
shown that combination of IL-2 and IL-15 increases Treg
proliferation [21,27]. We thus added titrated concentrations of
IL-2 (range 12,5 U/ml to 200 U/ml) with a fixed concentration of
IL-15 (10 ng/ml) to Treg cultures to determine the optimal IL-2
dose in our system. Concentrations of 25 U/ml or higher gave
similar results in terms of Treg yield (data not shown). We
therefore chose to use 25 U/ml IL-2 in combination with 10 ng/
ml IL-15 for expansion experiments.
To determine the optimal cycle length, cell numbers were
counted at several time points during primary and secondary
expansion cycles. Expansion values were calculated and are
depicted in Figure 6. In primary Treg expansion cycles with either
alloantigen or polyclonal stimulation, cultures reached maximal
cell numbers after 10–12 days. In secondary expansion cycles with
alloantigen stimulation, peak cell numbers were found at day 10.
In secondary expansion cycles with polyclonal stimulation, peak
cell numbers were found at day 10 if cells had been primed with
alloantigen. However, when Treg had been primed with
polyclonal stimulation, a plateau in cell numbers in a secondary
polyclonal stimulation cycle was reached around day 7. Since our
prime interest was to obtain alloantigen-specific Treg, the strategy
comprising two subsequent cycles with polyclonal stimulation
actually served as a control. Consequently, we standardized the
expansion cycle length at 10 days for all strategies.
Cell yield after Treg expansion with combined
alloantigen and polyclonal stimulation strategies
Having optimized the conditions for the primary and secondary
expansion cycles, we now isolated Treg and Tconv and
subsequently applied multiple expansion cycles according to the
strategies depicted in Figure 1. Average Treg expansion values are
shown in Figure 7. Contrary to our expectation that stimulation
cycles with alloantigen would provide lower cell yields as
compared to cycles of polyclonal expansion, Treg numbers
obtained after each of the four expansion strategies were similar
(average fold expansion 780, SD 300, p=0.71, N=4).
Phenotypic characterization of expanded Treg
A potential risk of Treg expansion is the outgrowth of
contaminating cell types such as CD8
pos T cells or NK-cells. In
our experiments, we did not find major contaminations, since
typically .90% of the expanded cells were CD4
pos T cells. The
Figure 2. Phenotypical and functional characteristics of freshly
MACS-isolated Treg. CD4
pos T cells were negatively isolated from
PBMC and separated into CD25
pos (Treg) and CD25
neg (Tconv) T cell
fractions by magnetic cell sorting. Data from a typical isolation is
shown. (A) Cell surface expression of CD25, CD127, CD27, CD70 and
CD62L, and intracellular expression of FoxP3 were analyzed on Treg
(black filled histograms) or Tconv (grey line histogram). (B) Proliferative
capacity of Treg or Tconv upon stimulation with HLA mismatched
gamma irradiated allogeneic PBMC was determined in the absence
(black bar) or presence (grey bar) of exogenous IL-2. Proliferation was
determined by measuring [
3H]Thymidine incorporation at day 5. (C)
Suppressive capacity of Treg in alloantigen responses was determined
in a MLR co-culture using [
3H]Thymidine incorporation. Autologous
naı ¨ve CD4
posCD25
neg Tresp cells were stimulated with HLA mismatched
gamma irradiated allogeneic PBMC. Treg (black lines) or Tconv (grey
lines) were added into these cultures at indicated Tresp:Treg/Tconv
ratios. Proliferation was determined by measuring [
3H]Thymidine
incorporation at day 5. Results are expressed as percentage of
[
3H]Thymidine incorporation +SD, indexed to [
3H]Thymidine incorpora-
tion of naı ¨ve Tresp and antigen only. (D) Suppressive capacity of Treg in
alloantigen responses was determined in a MLR co-culture using CFSE
dilution. CFSE labeled autologous naı ¨ve CD4
posCD25
neg Tresp cells were
stimulated with PKH26 labeled HLA mismatched gamma irradiated
allogeneic PBMC. Treg (black lines) or Tconv (grey lines) were added
into these cultures at indicated Tresp:Treg/Tconv ratios. Proliferation
was determined by measuring CFSE dilution of Tresp at day 5. Results
are expressed as percentage of proliferating cells, indexed to
percentages of proliferating cells in cultures of naı ¨ve Tresp and antigen
only. (E) Example CFSE of suppression assay as described in Figure 2D.
Tresp only (grey filled histogram), Tresp+Treg (1:1, black line) and
Tresp+Tconv (1:1, grey line) are shown, numbers indicate percentage of
proliferating cells, indexed to percentages of proliferating cells in
cultures of naı ¨ve Tresp and antigen only.
doi:10.1371/journal.pone.0002233.g002
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high, and
CD127
neg (Figure 8). The majority of Treg retained expression of
FoxP3
pos after two cycles of expansion. Tconv cells were largely
FoxP3
neg. Previously, we and others have shown that Treg
constitutively expressing CD27 are stronger suppressors [17,27].
Typically, after expansion, a portion of Treg retained a CD27
pos
phenotype, while the remaining Treg shifted towards a CD27
neg
phenotype. Treg expanded with two cycles of polyclonal
stimulation repeatedly showed the highest percentage of CD27
pos
cells (50 to 80%), while cells expanded with two subsequent
alloantigen stimulation cycles had the lowest percentage of
CD27
pos cells (10 to 40%). The two strategies with alternated
alloantigen and polyclonal stimulation cycles showed intermediate
percentages of CD27
pos cells. The expression of CD70, the ligand
for CD27, was reversely correlated with CD27 expression. CD62L
is also described as a marker for Treg with high suppressive
potency [24]. Whereas expression of CD62L was lost on expanded
Tconv cells, a substantial portion of Treg retained expression of
this marker.
Functional characterization of expanded Treg
Treg retain anergic properties after expansion. One of
the hallmarks of Treg is their anergic (hyporesponsive) behavior in
vitro. Treg retained their anergic state after expansion, irrespective
of the strategy employed, while in contrast Tconv were not
anergic. Indeed, Treg did not proliferate upon stimulation in
absence of exogenous T cell growth factors, while addition of IL-2
restored the proliferative capacity (Figure 9).
Expanded Treg show enhanced suppressive capacity and
can acquire full antigen-specificity within two expansion
cycles. The main characteristics of alloantigen-specific Treg
should be their strong suppressive capacity when stimulated by
target antigen (in transplantation settings this would be donor
antigen), in parallel with a lack of suppressive activity in the case of
stimulation by other antigens such as fully HLA mismatched third
party alloantigen. To assess suppressive capacity, we used both the
classic [
3H]Thymidine incorporation co-culture suppression assay
as well as a CFSE based assay. The latter is used because in some
instances it is difficult to draw clear conclusions from the
[
3H]Thymidine assay when using multiple cell populations.
Figure 10 shows that highly antigen-specific Treg were obtained
in two situations. Treg expanded with two cycles of alloantigen
stimulation showed very high suppressive activity in target antigen
driven MLR (.90% suppression in all ratios tested, Figure 10A)
and hardly any suppression of third party antigen driven MLR.
The cells obtained after the strategy starting off with a primary
allostimulation, followed by secondary polyclonal stimulation, also
yielded potent Treg with high antigen-specificity, as indicated by
strong suppression of target antigen driven responses (.50%
suppression with Tresp:Treg ratios of 16:1 or lower, Figure 10A)
and low inhibition of third party HLA mismatched allostimulated
MLR. Importantly, these data show that under these circum-
stances a very high degree of antigen-specificity can already be
obtained after two cycles of expansion. This is relevant since we
have noticed that multiple expansion cycles, irrespective of the
mode of stimulation, can lead to reduced suppressive capacity, cell
exhaustion, and subsequent cell death (data not shown). The
expansion strategy starting off with a primary polyclonal stimulus
followed by a secondary alloantigen stimulus yielded very potent
suppressors, showing .90% suppression of target antigen driven
MLC at all ratios tested (highest ratio tested 32:1, Figure 10A).
However, this cell population was still capable of suppression in
third party alloantigen driven responses, albeit at a much lower
efficiency than target antigen driven responses (.50% suppression
at Tresp:Treg ratios 2:1 or lower, Figure 10A), indicating a strong
enrichment Treg specific for target antigen, but incomplete
exclusion of Treg with other specificities. As expected, Treg
expanded with two cycles of polyclonal stimulation showed
suppression of both target antigen as well as 3
rd party alloantigen
driven MLR to a similar, moderate degree (.50% suppression at
8:1 and 4:1 or lower, respectively, Figure 10A). Treg displayed
similar suppressive activity in CFSE suppression assays, while
expanded Tconv were not suppressive (Figure 10B). Note that in
the [
3H]Thymidine based suppression assays (Figure 10A), the low
Figure 3. Determination of optimal strength of alloantigen Treg stimulation. (A) Treg were stimulated with indicated ratios of irradiated
allogeneic PBMC in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [
3H]Thymidine incorporation at day 5. Data are
representative of three independent experiments. (B) Treg primed with alloantigen were restimulated with indicated ratios of irradiated allogeneic
PBMC in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [
3H]Thymidine incorporation at day 3. Data are
representative of three independent experiments. (C) Efficiency of primary alloantigen stimulated expansion is related to the number of HLA-DRB1
mismatches. Freshly isolated Treg were expanded in one cycle in the presence of IL-2 and IL-15 and stimulation by gamma irradiated allogeneic
PBMC with one (N=10) or two (N=6) mismatches on HLA class II DRB1 genes. Expansion values were calculated by relating the number of cells set
up in the initial culture to the number of cells after expansion (after two days rest). Expansion was higher with alloantigen mismatched on two HLA-
DRB1 genes as compared to alloantigen with one mismatch. This difference was found to be statistically significant in a Mann Whitney test (P=0.025).
doi:10.1371/journal.pone.0002233.g003
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Tconv are not indicative of suppression per se, but rather a result
of the very early proliferation of already primed Tconv cells in the
co-culture. These cells heavily compete for medium components
with the naı ¨ve Tresp cells that respond later in time. Tconv
present in substantial numbers may indeed lead to distinct culture
kinetics with an earlier proliferation peak and a net result of lower
counts at day 5.
In summary, optimal results were obtained with Treg expansion
in two subsequent cycles of alloantigen stimulation: efficient
increases in cell numbers, yielding highly potent and strictly
antigen-specific Treg. The success of Treg expansion with
alternated alloantigen and polyclonal stimulation depends on the
order of the stimulation cycles. When Treg are expanded by a
primary alloantigen stimulus followed by a secondary polyclonal
stimulus, cells expand efficiently and show highly potent, strictly
antigen-specific suppressive capacity. The reverse strategy with a
primary polyclonal stimulus and a secondary alloantigen stimulus,
yield high numbers of cells, and enrichment for target antigen-
specific Treg. However, Treg specific for other antigens are still
present. As expected, two cycles of polyclonal stimulation yielded
high numbers of Treg. These cells were suppressive, but no
enrichment for alloantigen-specific Treg had taken place.
Discussion
High numbers of Treg will be needed for effective Treg
immunotherapy in humans to facilitate tolerance in patients with
auto-immunity or after transplantation. Ex vivo Treg expansion
can provide the solution to obtain these high numbers.
Therapeutic efficiency can be improved by selecting for target-
antigen reactive Treg, as indicated by preclinical mouse models
designed to study the prevention of autoimmunity [12–14] and
graft-versus-host disease [4,6,7]. At the same time, exclusion of
Treg with specificities for other antigens lowers the risk for
unwanted non-specific immune suppression, thus decreasing the
risk on opportunistic infections and tumor growth.
Information on strategies for large scale antigen-specific
expansion of human Treg is scant [22], as previous studies on ex
vivo Treg expansion have primarily focused on polyclonal
stimulation of Treg [16–21]. In the current report, we demonstrate
the ex vivo generation of Treg with direct alloantigen-specificity
from human naturally occurring CD4
posCD25
high Treg in as little
as two stimulation cycles, requiring primary stimulation with
HLA-mismatched allogeneic stimulator cells and IL-2 plus IL-15.
Experiments were performed with alternating allogeneic and
polyclonal (anti-CD3 anti-CD28 mAb) stimulation to define the ex
vivo conditions resulting in optimal enrichment of alloantigen-
specific Treg and high cell yield.
Naturally occurring CD4
posCD25
high Treg display a polyclonal
TCR V-beta pattern [28]. Stimulation of this polyclonal Treg
population with allogeneic stimulator APC has been shown to
specifically activate alloantigen-reactive Treg in mice [1,4,6,7,29,30]
and humans [27]. Thus, these studies indicate that it is feasible to
generate alloantigen-specific Treg from the naturally occurring
CD4
posCD25
high Treg population. Here, we elaborated on these
findings and questioned how to generate high numbers of
alloantigen-specific Treg starting with polyclonal CD4
posCD25
high
Treg populations obtained from peripheral blood. We specifically
focused ona magneticbead based method for Tregisolation, soasto
fit in with currently available clinical grade isolation tools, with the
objective to facilitate easy translation into clinical practice. Clinical
grade (Good Manufacturing Practice, GMP) CD4
posCD25
high Treg
isolation by a magnetic bead based method is now feasible using the
CliniMACS system [31,32], albeit that Treg purity is suboptimal
(50–60%). Our recent data on expansion of CliniMACS isolated
Treg confirms that the results reported here can indeed be
extrapolated to clinical grade purification (unpublished observa-
tions). Clearly, with regard to purity of the starting population
magnetic bead isolation is inferior to FACS sorting, but this latter
method isnotreadilyavailableforGMP purposes.Weobtainedwith
high purity FACS sorted Treg similar results regarding antigen
specificity, but with lower expansion rates and higher overall
suppressive capacity (unpublished observations).
To design a successful strategy for obtaining high numbers of
alloantigen-specific Treg, we hypothesized that it might be
beneficial to combine ex vivo expansion cycles applying polyclonal
stimulation, to boost expansion, and cycles applying alloantigen
stimulation, to selectively stimulate alloantigen-specific Treg. Our
data show that a high degree of alloantigen-specificity could be
obtained in as little as two cycles of expansion. To increase
alloantigen-specificity even more, it would be an option to repeat
alloantigen expansion stimulation for multiple cycles, which in
theory would progressively enrich for strictly antigen-specific Treg.
However, if Treg populations were expanded for more than two
expansion cycles, we observed a loss of suppressive capacity and
high cell death (unpublished results).
Although highest cell yields were expected after expansion with
two polyclonal stimulation cycles, our data showed similar cell
numbers for all strategies. This result may in part be due to the fact
that we opted for a standardized 10 day culture cycle. This choice
was made based on the fact that strategies comprising one or more
alloantigen stimulation cycles showed optimal expansion at day
10. However, expansion of cells in a second subsequent polyclonal
stimulation cycle reached an optimum at day 7, cell death
occurred thereafter.
Of note, the strategies described in this report generate Treg
with direct alloantigen-specificity. These cells may be especially of
benefit for patients receiving an HLA mismatched stem cell graft,
where this route of alloantigen-reactivity is important in graft
versus host pathology [33]. Although transplantation centers
pursue a high degree of HLA-matching to prevent harmful
reactions, HLA-locus mismatched and haploidentical transplants
are increasingly being performed [34]. In these cases current
immunosuppressive regimen may benefit from the addition of an
antigen-specific component. In solid organ transplantation, next to
direct alloantigen recognition, the indirect route of alloantigen
presentation clearly contributes to graft rejection [35]. With this in
mind, it was recently shown, that it is also feasible to obtain Treg
Figure 4. Determination of optimal mode and strength of primary polyclonal Treg stimulation. (A) Treg were stimulated with indicated
ratios of anti-CD3+ anti-CD28 microbeads or with indicated concentrations of platebound anti-CD3+ soluble anti-CD28 (1 mg/ml) in the presence of
IL-2 and IL-15. Proliferation was determined by measurement of [
3H]Thymidine incorporation at day 4. (B) Indexed cell yield after primary polyclonal
Treg culture using optimal strength of anti-CD3+ anti-CD28 microbeads (set to 100%) or platebound anti-CD3 plus soluble anti-CD28 stimulation. (C)
Cell division pattern and survival/death signals of Treg after different primary polyclonal stimulations. Treg were stained with CFSE and stimulated
with optimal strength of anti-CD3+ anti-CD28 microbeads or platebound anti-CD3+ soluble anti-CD28. CFSE dilution pattern, 7AAD staining and Bcl-2
expression of Treg population were assessed at day 4. In the lowest row, Bcl-2 expression is depicted gated on dividing Treg only. Data are
representative of four independent experiments.
doi:10.1371/journal.pone.0002233.g004
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dendritic cells pulsed with allo-HLA-peptides [36].
Recently, the first clinical trials on Treg immunotherapy have
been initiated; in these studies, either CliniMACS isolated
CD4
posCD25
high Treg or ex vivo manipulated CD4
pos T cell lines
containing induced regulatory Tr1 cells are being infused in
patients receiving stem cell transplantations [22]. So far, no effects
have been reported.
Figure 5. Determination of optimal mode and strength of secondary polyclonal Treg stimulation. (A) Treg were primed with anti-CD3+
anti-CD28 microbeads and restimulated with indicated ratios of anti-CD3+ anti-CD28 microbeads or with indicated concentrations of platebound
anti-CD3+ soluble anti-CD28 in the presence of IL-2 and IL-15. Proliferation was determined by measurement of [
3H]Thymidine incorporation at day 3.
(B) Indexed cell yield after secondary polyclonal Treg culture using optimal strength of anti-CD3+ anti-CD28 microbeads (set to 100%) or platebound
anti-CD3+ soluble anti-CD28 stimulation. (C) Cell division pattern and survival/death signals of Treg after different secondary polyclonal stimulations.
Treg were stained with CFSE and stimulated with optimal strength of anti-CD3+ anti-CD28 microbeads or platebound anti-CD3+ soluble anti-CD28.
CFSE dilution pattern, 7AAD staining and Bcl-2 expression of Treg population were assessed at day 4. Data are representative of four independent
experiments.
doi:10.1371/journal.pone.0002233.g005
Alloantigen-Specific Treg
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cycles. Treg were stimulated with CFSE-labeled alloantigen (solid line, solid circle) or polyclonal (dotted line, open circle) stimulus in the presence of IL-2
and IL-15. At indicated time points, Treg numbers were counted by FACS (excluding CFSE
pos allogeneic stimulator cells) and related to Treg numbers at
initialset up.(B)OptimallengthofsecondaryTregexpansion cycles.Tregwereprimedwithalloantigen(solidlines)orpolyclonal(dottedlines)stimulation
as indicated in the presence of IL-2 and IL-15 and rested for 2 days prior to restimulation. Cells were restimulated with CFSE-labeled alloantigen (solid
circles) or polyclonal stimulus (open circles) in the presence of IL-2 and IL-15. At indicated time points, Treg numbers were counted by FACS (excluding
CFSE
pos allogeneic stimulator cells) and related to Treg numbers at initial set up. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0002233.g006
Figure 7. Treg expansion after primary and secondary cycles with alternated alloantigen or polyclonal stimulation. Treg and Tconv
were expanded according the schedule in Figure 1 and rested for two days. Treg numbers were determined and related to Treg numbers at initial set
up. Data represent average expansion +SD of seven independent experiments.
doi:10.1371/journal.pone.0002233.g007
Alloantigen-Specific Treg
PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2233Figure 8. Phenotypical characterization of expanded Treg. Treg and Tconv were expanded according the schedule in Figure 1 and rested for
two days. Cell surface expression of CD25, CD127, CD27, CD70 and CD62L, and intracellular expression of FoxP3 was analyzed on Treg (black filled
histograms) or Tconv (grey line histogram). Data are representative of four to seven independent experiments.
doi:10.1371/journal.pone.0002233.g008
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human functional alloantigen-specific Treg in large numbers for
immunotherapeutic purposes. This may be a valuable aid in the
clinical application of Treg, aiming at clinical tolerance to selected
antigens, while minimizing general immune suppression.
Materials and Methods
Treg expansion strategies
To determine the optimal expansion strategy for obtaining high
numbers of functionally active human alloantigen-specific Treg
from CD4
posCD25
high Treg, we devised four different strategies,
consisting of two subsequent cycles of expansion with alternated
polyclonal and alloantigen-specific stimulation (Figure 1).
Cell preparation / isolation
Buffy coats were purchased from Sanquin bloodbank, Nijmegen,
The Netherlands. These buffy coats were obtained from healthy
human donors upon written informed consent with regard to
scientific use.
The current study did not require approval from an ethical
committee according to the Dutch Medical Research Involving
Human Subjects Act (WMO). PBMC were isolated by density
gradient centrifugation (Lymphoprep, Nycomed Pharma, Ros-
kilde, Denmark). CD4
pos T cells were negatively selected using
mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16
(3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) (all
from BD Biosciences, San Jose, CA), and CD56 (MOC-1) (Dako,
Glostrup, Denmark) combined with sheep-anti-mouse-IgG coated
magnetic beads (Dynal Biotech, Oslo, Norway), routinely resulting
in a .90% pure CD4
pos T cell fraction. CD25
high Treg and
CD25
neg conventional T cells were separated by MACS-sorting,
using 10 ml anti-CD25 magnetic microbeads / 10
7 CD4
pos cells
(Miltenyi Biotec, Bergisch Gladbach, Germany). HLA typing was
performed by serological and DNA based techniques according to
international (ASHI/EFI) standards [37].
CD4
posCD25
high Treg expansion
Cell cultures were performed in 96-well round bottom plates
with culture medium consisting of RPMI 1640 supplemented with
pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 mg/
ml), and 10% human pooled serum (HPS), in a 37
oC, 95%
humidity, 5% CO2 incubator.
To optimize Treg expansion conditions, the mode and strength of
stimulation, exogenous cytokine concentration, and expansion cycle
length were varied in early experiments, as reported in the Results
section. For assessment of cell division using CFSE, 1–5610
6 cells
were labeled with 0.5 mM CFDA-SE (Molecular Probes) prior to
stimulation. The final expansion protocols are described below.
For primary and secondary cycle alloantigen-specific expansion,
2.5610
4 T cells were cultured with 10
5 irradiated (30 Gy) HLA
mismatched allogeneic PBMC (target alloantigen, ratio al-
loPBMC:Treg = 4:1).
For first cycle polyclonal expansion, 2.5610
4 T cells were
cultured with 1.25610
4 anti-CD3+ anti-CD28 coated microbeads
(Dynal Biotech). For secondary cycle polyclonal expansion,
2.5610
4 Treg were cultured with 5 mg/ml platebound anti-CD3
(UCHT1, BD Biosciences, 4 hours in PBS in incubator) plus
1 mg/ml soluble anti-CD28 (CD28.2, BD Biosciences).
Exogenous rhIL-2 (25 U/ml, Chiron, Amsterdam, the Nether-
lands) and rhIL-15 (10 ng/ml BioSource International, Camarillo,
CA) were added to all expansion cultures. Wells were split and fresh
medium containing cytokines was added every 3 days. After 10 days,
the cells were harvested, washed and rested for 2 days in 5% HPS
culture medium with 5 ng/ml rhIL-15 before analysis or further
expansion. In all experiments, Tconv were included as control.
Flow cytometry
The phenotype of cells was analyzed by five-color flow cytometry
(FC500, Beckman Coulter, Fullerton, CA). For cell surface staining,
the following conjugated mAbs were used: CD25(M-A251)-PE,
CD70(Ki-24)-PE, CD127(hIL-7R-M21)-AlexaFluor647 (BD Biosci-
ences), CD27(M-T271)-FITC (Dako), CD4-(SFCI12T4D11)-PCy7
Figure 9. Proliferative capacity of expanded Treg. Treg and Tconv were expanded according the schedule in Figure 1 and rested for two days.
Proliferative capacity of expanded cells upon restimulation with target alloantigen (same as used for expansion) was determined in the absence
(black bars) or presence (grey bars) of IL-2. Proliferation was determined by measuring [
3H]Thymidine incorporation at day 3. Results are expressed as
percentage of [
3H]Thymidine incorporation +SD. Data are representative of four independent experiments.
doi:10.1371/journal.pone.0002233.g009
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PLoS ONE | www.plosone.org 11 May 2008 | Volume 3 | Issue 5 | e2233and CD62L(DREG56)-ECD (Beckman Coulter). To stain apoptotic
cells, 7-amino-actinomycin-D (7AAD, Sigma-Aldrich, Zwijndrecht,
the Netherlands) was added to cells prior to acquisition. For
intracellular staining, Fix and Fix/Perm buffer (eBioscience, San
Diego, CA) were used according to the manufacturer’s instructions
incombinationwithFoxP3(259D/C7)-AlexaFluor647orBcl-2(100)-
PE (BD Biosciences). Isotype controls were used for gate settings. In
some experiments, cell were counted by flowcytometry using Flow-
Count fluorospheres (Beckman Coulter).
Stimulation assay to analyze T cell anergy
T cell anergy was examined in (re-)stimulation assays. 2.5610
4
cells were stimulated with 10
5 irradiated allogeneic stimulator
PBMC in the presence or absence of IL-2 (12.5 U/ml). Classically,
T cell anergy is defined as a low proliferative capacity upon
stimulation with antigen only, which can be reversed by addition
of exogenous IL-2. Proliferation was measured at indicated time-
points by determination of [
3H]Thymidine incorporation as
described above. Tests were set up in triplicate; results are
expressed as mean+SD counts per 5 minutes.
Co-culture suppression assay
Suppressive capacity of Treg was studied in mixed lymphocyte
reaction (MLR) co-culture suppression assays. Proliferation was
determined by either [
3H]Thymidine incorporation or CFSE
dilution assays.
For assessment of cell division using [
3H]Thymidine, 5610
4
naive autologous CD4
posCD25
neg T responder cells were
stimulated with 10
5 irradiated allogeneic stimulator PBMC (either
target PBMC or HLA mismatched third party PBMC). Treg or
Tconv were titrated into the cultures. Proliferation was measured
at day 5. To this end, 0.5 mCi [
3H]Thymidine (Amersham
Biosciences, Piscataway, NJ) was added to each well. After
8 hours, [
3H]Thymidine incorporation was measured using a
beta-plate counter (Packard, Canberra, Australia). Tests were set
up in triplicate; [
3H]Thymidine incorporation were expressed as
mean+SD counts per 5 minutes.
For assessment of cell division using CFSE dilution, naı ¨ve
autologous 5–10610
6 CD4
posCD25
neg T responder cells were
labeled with 1 mM CFDA-SE (Molecular Probes) prior to
stimulation, and allogeneic stimulator PBMC were labeled with
2 mM PKH26 (Sigma-Aldrich). 2.5610
4 CFSE
pos T responder
cells were stimulated with 10
5 PKH26
pos irradiated allogeneic
stimulator PBMC (either target PBMC or HLA mismatched third
party PBMC). Unlabeled Treg or Tconv were titrated into the
cultures. At day 5, 7-amino-actinomycin-D (7AAD, Sigma-
Aldrich) was added to the samples. Tresp division was analyzed
by flow cytometry (FC500, Beckman Coulter, Fullerton, CA),
excluding 7AAD
pos cells, PKH26
pos stimulator cells and CFSE
neg
Treg or Tconv and expressed as percentage dividing cells.
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